United States: JTEKT v. GKN: Federal Circuit Finds Competitor Lacks Standing To Appeal PTAB's Final Written Decision

Last Updated: September 11 2018
Article by Lisa M. Mandrusiak


After determining that its competitor GKN's patent raised a potential risk of infringement for a product under development, JTEKT1 challenged the patentability of claims 1–7 of U.S. Patent No. 8,215,440 via inter partes review (IPR2016-00046). When claims 2 and 3 were confirmed as patentable in the final written decision—and thus the risk of infringement remained—JTEKT appealed, and GKN moved to dismiss the appeal based on lack of standing.

To establish standing, a party must show that they have (1) suffered an injury in fact, (2) that is fairly traceable to the challenged conduct, and (3) that is likely to be redressed by a favorable judicial decision. Phigenix, Inc. v. ImmunoGen, Inc., 845 F.3d 1168, 1171 (Fed. Cir. 2017) (citing Spokeo, Inc. v. Robins, 136 S. Ct. 1540, 1547 (2016)).

In its briefing, JTEKT asserted it had (i) injury based on the potential risk of infringement, (ii) economic injury, and (iii) injury based on the IPR estoppel provisions. But, the panel found that JTEKT failed to establish an actual injury sufficient to confer Article III standing and dismissed the appeal. Specifically, the panel found that because there is no final product, JTEKT cannot definitively say whether it will infringe the '440 patent and that the potential risk of infringement is impossible to quantify at this time. As such, the panel said there is insufficient proof of an injury in fact.

Request for Rehearing

On September 4, 2018 JTEKT filed a combined petition for panel rehearing and rehearing en banc. In JTEKT's petition, it asserts that the panel overlooked and/or misapprehended facts and evidence demonstrating JTEKT's potential risk for infringement and that the panel did not address JTEKT's economic injury at all.

JTEKT also argued that rehearing en banc is necessary because the issue has consequences beyond JTEKT and GKN's dispute. By limiting standing to definitive patent-inflicted injury associated with an infringement suit, the panel's decision risks creating overly-narrow, patent-specific standing jurisprudence that does not consider the broader law necessary to address standing in appeals from all agency actions. And even for patent cases, this unnecessarily narrow view of standing undercuts the effectiveness of the IPR scheme and works to discourage these types of administrative proceedings because petitioners faced with invalid competitor patents during the product design process may have no recourse following an adverse FWD. Denying appeal access to direct competitors such as JTEKT is inconsistent with congressional intent and has the potential to affect thousands of companies who want to do their due diligence before finalizing development or entering commercial production.

JTEKT requested rehearing en banc to answer two questions:

  1. Whether the estoppel provisions of the IPR statute independently constitute a real and substantial injury sufficient to establish standing between competitors; and
  2. Whether the panel's decision erroneously limits an injury in fact sufficient to establish standing to definitive patent-inflicted injury when this determination is contrary to both the statutes establishing standing and case law establishing standing based on other types of injury such as economic injury.

Appellant standing from IPR final written decisions is currently a hot-button issue, and several panels appear to have invited the en banc court to weigh in at least on the estoppel issue. In Consumer Watchdog, the Court noted that it "leaves it to future panels to decide whether, under other circumstances, the preclusive effect of the estoppel provisions could constitute an injury in fact." Consumer Watchdog v. Wis. Alumni Research Found., 753 F.3d 1258, 1263 (Fed. Cir. 2014). And in Altaire, the panel said "we do not decide whether this potential estoppel effect is sufficient independently to establish standing." Altaire Pharms., Inc. v. Paragon Bioteck, Inc. 889 F.3d 1274, 1283 (Fed. Cir. 2018).

Moreover, the issue of standing to appeal from final written decisions has been presented to the Supreme Court in RPX Corp. v. ChanBond LLC.

RPX v. Chanbond

In RPX, the PTO determined that RPX had not shown that the claims were unpatentable. RPX appealed to the Federal Circuit and Chanbond filed a motion to dismiss RPX's appeal for lack of standing. Chanbond argued that, while it was asserting the patent in litigation, RPX was not a party to that litigation and could not show an injury sufficient for standing. RPX responded, emphasizing that Congress granted RPX the statutory right to challenge patents, and failure to follow through (i.e., dismissing the appeal and allowing the final written decision to stand) constitutes an injury. RPX also alleged that the PTO's decision tarnished its reputation, constituting economic injuries. But the Federal Circuit agreed with Chanbond, and dismissed the appeal for lack of standing. In short, the Federal Circuit held that the statute guaranteed RPX the right to file an IPR, not the right to win, and thus there was no injury. The Court also concluded that the evidence submitted did not sufficiently prove that RPX would face increased competition or had tarnished its reputation because the declarant conceded that he was "unable to quantify the reputational and economic harm" suffered by RPX.

In its petition for writ of certiorari, RPX argues that the Federal Circuit's opinion is contrary to the IPR statutes, specifically when Congress has (i) statutorily created the right to have the PTO cancel patent claims when the petitioner has met its burden; (ii) statutorily created the right for parties dissatisfied with a decision to appeal to the Federal Circuit; and (iii) statutorily created an estoppel prohibiting the petitioner from challenging the patent claims again. In short, RPX alleges that the Federal Circuit has limited standing to discount any injury not inflicted by the patent itself (i.e., infringement). RPX also asserted that this is a good candidate for certiorari because the Federal Circuit has issued multiple decisions on the issue and has exclusive jurisdiction over appeals from the Board.

Several parties filed briefs in support of the writ of certiorari, Askeladden LLC, The Initiative for Medicines Access & Knowledge, Patients for Affordable Drugs, Inc., and the New York Intellectual Property Law Association.

The Supreme Court is scheduled to consider the petition at its September 24 conference and should issue a decision soon after.

The Federal Circuit has yet to respond to JTEKT's petition for rehearing.


1 JTEKT is represented by Oblon.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions